Dynamics and visualization of MCF7 adenocarcinoma cell death by aptamer-C1q-mediated membrane attack

Nucleic Acid Therapeutics

Volumn 22, Issue 4, 2012, Pages 275-282

  Stecker, John R ^a   Savage, Alissa A ^b   Bruno, John G ^b   García, Dana M ^a   Koke, Joseph R ^a  

^a Texas State University San Marcos   (United States)

^b Operational Technologies Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; COMPLEMENT COMPONENT C1Q; COMPLEMENT MEMBRANE ATTACK COMPLEX; STREPTAVIDIN;

BIOTINYLATION; BREAST ADENOCARCINOMA; CELL DEATH; CELL MEMBRANE; CELL MEMBRANE DEPOLARIZATION; CELL STRAIN MCF 7; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOLYSIS; DNA BINDING; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HUMAN CELL; IMMUNOGOLD LABELING; IN VITRO STUDY; INNATE IMMUNITY; OSMOSIS; PRIORITY JOURNAL; REVIEW; TRANSMISSION ELECTRON MICROSCOPY;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; APTAMERS, NUCLEOTIDE; BREAST NEOPLASMS; CELL DEATH; CELL MEMBRANE; CELL SHAPE; COMPLEMENT ACTIVATION; COMPLEMENT C1Q; FLUORESCENCE RESONANCE ENERGY TRANSFER; FLUORESCENT DYES; HUMANS; MCF-7 CELLS; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON, TRANSMISSION; STREPTAVIDIN;

EID: 84865427364     PISSN: 21593337     EISSN: None     Source Type: Journal    
DOI: 10.1089/nat.2012.0355     Document Type: Review

References (28)

1. BARRETT, A., ROQUES, T., SMALL, M., and SMITH, R.D. (2006). How much will Herceptin really cost? Br. Med. J. 333, 1118-1120. (Pubitemid 44863653)
2. BITTAR, N., KOKE, J.R., BERKOFF, H.A., and KAHN D.R. (1975). Histochemical and ultrastructural changes in human myocardial cells after cardiopulmonary bypass. Circulation. 52, 16-25.
3. BOUCHARD, P.R., HUTABARAT, R.M., and THOMPSON, K.M. (2010). Discovery and development of therapeutic aptamers. Ann. Rev. Pharmacol. Toxicol. 50, 237-257.
4. BRUNO, J.G. (2010). Aptamer-biotin-streptavidin-C1q complexes can trigger the classical complement pathway to kill cancer cells. In vitro Cell. Dev. Biol. Animal. 46, 107-113.
5. BRUNO, J.G., CARRILLO, M.P., and PHILLIPS, T. (2008). In vitro antibacterial effects of antilipopolysaccharide DNA aptamer-C1qrs complexes. Folia Microbiol. (Praha) 53, 295-302.
6. BRUNO, J.G., and CROWELL, R. (2008). Selective glutaraldehydemediated coupling of proteins to the 3'-adenine terminus of polymerase chain reaction products. J. Biomol. Tech. 19, 177-183.
7. BRUNO, J.G., and MINER, J.C. (2011). Therapeutic Nucleic Acid-3'-Conjugates. U.S. Patent No. 7,910,297.
8. CHAN, A.K., LOCKHART, D.C., VON BERNSTORFF, W., SPANJAARD, R.A., JOO, H.G., EBERLEIN, T.J., and GOEDEGEBUURE, P.S. (1999). Soluble MUC1 secreted by human epithelial cancer cells mediates immune suppression by blocking T-cell activation. Int. J. Cancer. 82, 721-726. (Pubitemid 29356972)
9. CHU, T.C., MARKS, J.W., LAVERY, L.A., FAULKNER, S., ROSENBLUM, M.G., ELLINGTON, A.D., and LEVY, M. (2006). Aptamer:toxin conjugates that specifically target prostate tumor cells. Cancer Res. 66, 5989-5992.
10. CROMEY, D.W. (2010). Avoiding twisted pixels: ethical guidelines for the appropriate use and manipulation of scientific digital images. Sci. Eng. Ethics 16, 639-667.
11. DONIN, N., JURIANZ, K., ZIPOREN, L., SCHULTZ, S., KIRSCHFINK, M., and FISHELSON, Z. (2003). Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid. Clin. Exp. Immunol. 131, 254-263. (Pubitemid 36205136)
12. DOUGAN, H., LYSTER, D.M., VO, C.V., STAFFORD, A., WEITZ, J.I., and HOBBS, J.B. (2000). Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood. Nucl. Med. Biol. 27, 289-297. (Pubitemid 30314723)
13. FARKAS, I., BARANYI, L., ISHIKAWA, Y., OKADA, N., BOHATA, C., BUDAI, D., FUKUDA, A., IMAI, M., and OKADA, H. (2002). CD59 blocks not only the insertion of C9 into MAC but inhibits ion channel formation by homologous C5b-8 as well as C5b-9.J. Physiol. 539, 537-545. (Pubitemid 35175407)
14. FERREIRA, C.S., MATTHEWS, C.S., and MISSAILIDIS, S. (2006). DNA aptamers that bind to MUC1 tumour marker: design and characterization of MUC1-binding single-stranded DNA aptamers. Tumour Biol. 27, 289-301. (Pubitemid 44646223)
15. FERREIRA, C.S., PAPAMICHAEL, K., GUILBAULT, G., SCHWARZACHER, T., GARIEPY, J., and MISSAILIDIS, S. (2008). DNA aptamers against the MUC1 tumour marker: design of aptamer-antibody sandwich ELISA for the early diagnosis of epithelial tumours. Anal. Bioanal. Chem. 390, 1039-1050. (Pubitemid 351207802)
16. FERREIRA, C.S.M., CHEUNG, M.C., MISSAILIDIS, S., BISLAND, S., and GARIEPY, J. (2009). Phototoxic aptamers selectively enter and kill epithelial cancer cells. Nucl. Acids Res. 37, 866-876.
17. FOLTS, J.D., SHUG, A.L., KOKE, J.R., and BITTAR, N. (1978). Protection of the ischemic myocardium with L-carnitine. Amer. J. Cardiol. 41, 1209-1214.
18. HALULINEN, J., and MERI, S. (1998). Complement-mediated killing of microtumors in vitro. Am. J. Pathol. 153, 845-855. (Pubitemid 28419037)
19. HARDING, F.A., STICKLER, M.M., RAZO, J., and DUBRIDGE, R.B. (2010). The immunogenicity of humanized and fully human antibodies: Residual immunogenicity resides in the CDR regions. MAbs. 2, 256-265.
20. JAYASENA, S.D. (1999). Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin. Chem. 45, 1628-1650. (Pubitemid 29419030)
21. JURIANZ, K., MASLAK, S., GARCIA-SCHULER, H., FISHELSON, Z., and KIRSCHFINK, M. (1999). Neutralization of complement regulatory proteins augments lysis of breast carcinoma cells targeted with rhumAb anti-HER2.Immunopharmacol. 42, 209-218. (Pubitemid 29322304)
22. KOKE, J.R., SHUG, A.L., FOLTS, J.D., and BITTAR, N. (1976). Ultrastructural and physiological changes induced in the canine myocardium by atractyloside. Cytobios. 17, 211-229.
23. LI, S., XU, H., DING, H., HUANG, Y., CAO, X., YANG, G., LI, J., XIE, Z., MENG, Y., LI, X., ZHAO, Q., SHEN, B., and SHAO, N. (2009). Identification of an aptamer targeting hnRNP A1 by tissue slide-based SELEX. J. Pathol. 218, 327-336.
24. MENG, L., YANG, L., ZHAO, X., ZHANG, L., ZHU, H., LIU, C., and TAN, W. (2012) Targeted delivery of chemotherapy agents using a liver cancer-specific aptamer. PLoS One. 7, e33434.
25. PENDERGAST, P.S., MARSH, H.N., GRATE, D., HEALY, J.M., and STANTON, M. (2005). Nucleic acid aptamers for target validation and therapeutic applications. J. Biomolec. Techniques. 16, 224-234.
26. WANG, S.Y., and WEINER, G. (2008). Complement and cellular cytotoxicity in antibody therapy of cancer. Expert Opin. Biol. Ther. 8, 759-768. (Pubitemid 351860205)
27. WEIGUM, S.E., FLORIANO, P.N., REDDING, S.W., YEH, C.K., WESTBROOK, S.D., MCGUFF, H.S., LIN, A., MILLER, F.R., VILLARREAL, F., ROWAN, S.D., VIGNESWARAN, N., WILLIAMS, M.D., and MCDEVITT, J.T. (2010). Nano-bio-chip sensor platform for examination of oral exfoliative cytology. Cancer Prev. Res. (Phila) 3, 518-528.
28. YAN, J., ALLENDORF, D.J., LI, B., YAN, R., HANSEN, R., and DONEV, R. (2008). The role of membrane complement regulatory proteins in cancer immunotherapy. Adv. Exp. Med. Biol. 632, 159-174.